{"id":9552,"date":"2024-10-14T13:55:06","date_gmt":"2024-10-14T11:55:06","guid":{"rendered":"https:\/\/syva.es\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/"},"modified":"2024-10-19T14:44:50","modified_gmt":"2024-10-19T12:44:50","slug":"the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3","status":"publish","type":"post","link":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/","title":{"rendered":"The DGAV, authorized SYVAZUL BTV3, Syva’s vaccine against bluetongue serotype 3."},"content":{"rendered":"

The DGAV (General Directorate of Food and Veterinary in Portugal) grants authorization under Art. 110 (2) of Regulation (EU) 2019\/6 for the emergency use of Syvazul BTV3 on Thursday 10 October.<\/strong><\/p>\n

Syva announces that the first doses of its Syvazul BTV3 vaccine will be available in Portugal to initiate immunisation against the disease in the coming weeks.<\/strong><\/p>\n

<\/strong>In September 2023, Bluetongue serotype 3 was detected for the first time in the Netherlands and spread rapidly to neighbouring countries. In September 2024, the first outbreaks were detected in the region of \u00c9vora, and subsequently in Spain, with vaccination starting in early October in Spain. Bluetongue serotype 3 has been particularly aggressive in both sheep and cattle, causing high mortality in sheep and severe clinical signs in cattle.<\/p>\n

Vaccination is the most effective method to control Bluetongue.<\/strong><\/p>\n

Syvazul BTV3 is indicated for active immunization of sheep and cattle to reduce the clinical symptoms and viraemia caused by Bluetongue serotype 3. Syvazul BTV3 is a vaccine against Bluetongue serotype 3 that has been granted temporary authorization for use in the Netherlands, Belgium, Germany, Austria, Spain and Portugal in accordance with Art. 110 (2) of Regulation (EU) 2019\/6. It is also approved for emergency use in the UK. Since the first authorization, more than 4 million doses have already been applied in these countries. For more information : https:\/\/www.dgav.pt\/destaques\/conteudo\/autorizacao-temporaria-de-utilizacao-da-vacina-syvazul-btv-3\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The DGAV granted authorization, under Art. 110 (2) of Regulation (EU) 2019\/6, for the emergency use of Syvazul BTV3 on Thursday 10 October. Syva announces that the first doses of its Syvazul BTV3 vaccine in Portugal will be available to initiate immunization against the disease in the coming weeks. <\/p>\n","protected":false},"author":4,"featured_media":9545,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[2176,53],"tags":[2240,2241,2108],"class_list":["post-9552","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-uncategorized","tag-bluetongue","tag-btv3-en","tag-vaccine"],"acf":[],"yoast_head":"\nThe DGAV, authorized SYVAZUL BTV3, Syva's vaccine against bluetongue serotype 3. - Syva<\/title>\n<meta name=\"description\" content=\"The DGAV granted authorization, under Art. 110 (2) of Regulation (EU) 2019\/6, for the emergency use of Syvazul BTV3 on Thursday 10 October. Syva announces that the first doses of its Syvazul BTV3 vaccine in Portugal will be available to initiate immunization against the disease in the coming weeks.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The DGAV, authorized SYVAZUL BTV3, Syva's vaccine against bluetongue serotype 3. - Syva\" \/>\n<meta property=\"og:description\" content=\"The DGAV granted authorization, under Art. 110 (2) of Regulation (EU) 2019\/6, for the emergency use of Syvazul BTV3 on Thursday 10 October. Syva announces that the first doses of its Syvazul BTV3 vaccine in Portugal will be available to initiate immunization against the disease in the coming weeks.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Syva\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-14T11:55:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-19T12:44:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1092\" \/>\n\t<meta property=\"og:image:height\" content=\"843\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline De Siron\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline De Siron\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/\"},\"author\":{\"name\":\"Caroline De Siron\",\"@id\":\"https:\/\/syva.es\/en\/#\/schema\/person\/b0533ddea617c5f83a24ca71d8152052\"},\"headline\":\"The DGAV, authorized SYVAZUL BTV3, Syva’s vaccine against bluetongue serotype 3.\",\"datePublished\":\"2024-10-14T11:55:06+00:00\",\"dateModified\":\"2024-10-19T12:44:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/\"},\"wordCount\":226,\"publisher\":{\"@id\":\"https:\/\/syva.es\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg\",\"keywords\":[\"Bluetongue\",\"BTV3\",\"vaccine\"],\"articleSection\":[\"Press release\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/\",\"url\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/\",\"name\":\"The DGAV, authorized SYVAZUL BTV3, Syva's vaccine against bluetongue serotype 3. - Syva\",\"isPartOf\":{\"@id\":\"https:\/\/syva.es\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg\",\"datePublished\":\"2024-10-14T11:55:06+00:00\",\"dateModified\":\"2024-10-19T12:44:50+00:00\",\"description\":\"The DGAV granted authorization, under Art. 110 (2) of Regulation (EU) 2019\/6, for the emergency use of Syvazul BTV3 on Thursday 10 October. Syva announces that the first doses of its Syvazul BTV3 vaccine in Portugal will be available to initiate immunization against the disease in the coming weeks.\",\"breadcrumb\":{\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#primaryimage\",\"url\":\"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg\",\"contentUrl\":\"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg\",\"width\":1092,\"height\":843},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/syva.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The DGAV, authorized SYVAZUL BTV3, Syva's vaccine against bluetongue serotype 3.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/syva.es\/en\/#website\",\"url\":\"https:\/\/syva.es\/en\/\",\"name\":\"Syva\",\"description\":\"Soluciones con sentido para la salud animal\",\"publisher\":{\"@id\":\"https:\/\/syva.es\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/syva.es\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/syva.es\/en\/#organization\",\"name\":\"Syva\",\"url\":\"https:\/\/syva.es\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/syva.es\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/syva.es\/wp-content\/uploads\/2019\/11\/syva-favicon.png\",\"contentUrl\":\"https:\/\/syva.es\/wp-content\/uploads\/2019\/11\/syva-favicon.png\",\"width\":512,\"height\":512,\"caption\":\"Syva\"},\"image\":{\"@id\":\"https:\/\/syva.es\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/syva.es\/en\/#\/schema\/person\/b0533ddea617c5f83a24ca71d8152052\",\"name\":\"Caroline De Siron\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/syva.es\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1860af197c9ab5760253262956f1e263?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1860af197c9ab5760253262956f1e263?s=96&d=mm&r=g\",\"caption\":\"Caroline De Siron\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The DGAV, authorized SYVAZUL BTV3, Syva's vaccine against bluetongue serotype 3. - Syva","description":"The DGAV granted authorization, under Art. 110 (2) of Regulation (EU) 2019\/6, for the emergency use of Syvazul BTV3 on Thursday 10 October. Syva announces that the first doses of its Syvazul BTV3 vaccine in Portugal will be available to initiate immunization against the disease in the coming weeks.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/","og_locale":"en_US","og_type":"article","og_title":"The DGAV, authorized SYVAZUL BTV3, Syva's vaccine against bluetongue serotype 3. - Syva","og_description":"The DGAV granted authorization, under Art. 110 (2) of Regulation (EU) 2019\/6, for the emergency use of Syvazul BTV3 on Thursday 10 October. Syva announces that the first doses of its Syvazul BTV3 vaccine in Portugal will be available to initiate immunization against the disease in the coming weeks.","og_url":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/","og_site_name":"Syva","article_published_time":"2024-10-14T11:55:06+00:00","article_modified_time":"2024-10-19T12:44:50+00:00","og_image":[{"width":1092,"height":843,"url":"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg","type":"image\/jpeg"}],"author":"Caroline De Siron","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Caroline De Siron","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#article","isPartOf":{"@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/"},"author":{"name":"Caroline De Siron","@id":"https:\/\/syva.es\/en\/#\/schema\/person\/b0533ddea617c5f83a24ca71d8152052"},"headline":"The DGAV, authorized SYVAZUL BTV3, Syva’s vaccine against bluetongue serotype 3.","datePublished":"2024-10-14T11:55:06+00:00","dateModified":"2024-10-19T12:44:50+00:00","mainEntityOfPage":{"@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/"},"wordCount":226,"publisher":{"@id":"https:\/\/syva.es\/en\/#organization"},"image":{"@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#primaryimage"},"thumbnailUrl":"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg","keywords":["Bluetongue","BTV3","vaccine"],"articleSection":["Press release"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/","url":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/","name":"The DGAV, authorized SYVAZUL BTV3, Syva's vaccine against bluetongue serotype 3. - Syva","isPartOf":{"@id":"https:\/\/syva.es\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#primaryimage"},"image":{"@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#primaryimage"},"thumbnailUrl":"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg","datePublished":"2024-10-14T11:55:06+00:00","dateModified":"2024-10-19T12:44:50+00:00","description":"The DGAV granted authorization, under Art. 110 (2) of Regulation (EU) 2019\/6, for the emergency use of Syvazul BTV3 on Thursday 10 October. Syva announces that the first doses of its Syvazul BTV3 vaccine in Portugal will be available to initiate immunization against the disease in the coming weeks.","breadcrumb":{"@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#primaryimage","url":"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg","contentUrl":"https:\/\/syva.es\/wp-content\/uploads\/2024\/10\/CORTADA-Portugal-ATU-BTV3-AdobeStock_489667079.jpeg","width":1092,"height":843},{"@type":"BreadcrumbList","@id":"https:\/\/syva.es\/en\/the-dgav-authorized-syvazul-btv3-syvas-vaccine-against-bluetongue-serotype-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/syva.es\/en\/"},{"@type":"ListItem","position":2,"name":"The DGAV, authorized SYVAZUL BTV3, Syva's vaccine against bluetongue serotype 3."}]},{"@type":"WebSite","@id":"https:\/\/syva.es\/en\/#website","url":"https:\/\/syva.es\/en\/","name":"Syva","description":"Soluciones con sentido para la salud animal","publisher":{"@id":"https:\/\/syva.es\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/syva.es\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/syva.es\/en\/#organization","name":"Syva","url":"https:\/\/syva.es\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/syva.es\/en\/#\/schema\/logo\/image\/","url":"https:\/\/syva.es\/wp-content\/uploads\/2019\/11\/syva-favicon.png","contentUrl":"https:\/\/syva.es\/wp-content\/uploads\/2019\/11\/syva-favicon.png","width":512,"height":512,"caption":"Syva"},"image":{"@id":"https:\/\/syva.es\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/syva.es\/en\/#\/schema\/person\/b0533ddea617c5f83a24ca71d8152052","name":"Caroline De Siron","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/syva.es\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1860af197c9ab5760253262956f1e263?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1860af197c9ab5760253262956f1e263?s=96&d=mm&r=g","caption":"Caroline De Siron"}}]}},"modified_by":null,"_links":{"self":[{"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/posts\/9552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/comments?post=9552"}],"version-history":[{"count":0,"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/posts\/9552\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/media\/9545"}],"wp:attachment":[{"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/media?parent=9552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/categories?post=9552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/syva.es\/en\/wp-json\/wp\/v2\/tags?post=9552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}